8-K: HeartSciences Raises $5.2M, Reduces Debt via Equity

HeartSciences Inc. announced it has raised $5.2 million through its Regulation A offering and reduced $1.655 million in debt by issuing common stock.

Summary

• Completed several closings of its Regulation A offering, raising $5.2 million in gross proceeds out of a maximum target of $15 million.
• Issued 1,484,440 Units, with each unit consisting of one share of Series D Preferred Stock and one warrant to purchase common stock at $5.00 per share.
• 979,851 shares of Series D Preferred Stock have been converted into an equal number of common stock shares.
• Exchanged $1,655,000 of an unsecured promissory note, originally issued in September 2024, for 461,572 shares of common stock, thereby reducing the principal debt.
• Total common stock issued and outstanding is 2,535,066 shares as of August 22, 2025, following these transactions.

Sentiment

Score: 5

Explanation: While the company successfully raised capital and reduced debt, the capital raise was significantly below its maximum target, and both transactions resulted in substantial dilution for common shareholders.

Positives

• Successfully raised $5.2 million in gross proceeds through the Regulation A offering, providing capital for company operations.
• Reduced outstanding debt by $1,655,000 through a debt-for-equity exchange, which improves the company's balance sheet.

Negatives

• The Regulation A offering has only secured $5.2 million out of a maximum target of $15 million, indicating a significant shortfall from the potential capital raise.
• The issuance of 1,484,440 Units, the conversion of 979,851 Series D Preferred shares, and the issuance of 461,572 common shares for debt exchange result in substantial dilution for existing common stockholders.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders (Common Stock): Experience dilution due to the issuance of new common stock from Series D Preferred conversions and the debt exchange.
• Series D Preferred Stockholders: Have the option to convert to common stock, potentially benefiting from future common stock appreciation.
• Warrant Holders: Hold the right to purchase common stock at $5.00, providing potential upside if the stock price exceeds this.
• Creditors: The specific third-party creditor whose note was exchanged for equity has seen their debt reduced, converting them into equity holders.

Key Dates

Recommendation

The company successfully raised capital and reduced debt, which are positive steps for financial stability. However, the capital raise fell significantly short of its maximum target, and both the offering and debt exchange resulted in substantial dilution for common shareholders. The long-term impact depends on how the raised capital is utilized and the company's future performance, warranting a 'hold' until further operational updates are provided.

Keywords

HeartSciences, HSCS, Regulation A Offering, Capital Raise, Debt Exchange, Common Stock, Preferred Stock, Warrants, SEC Filing, Financial Health, Dilution